A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate

Molecular Genetics and Metabolism

Volumn 93, Issue 4, 2008, Pages 381-387

  Han, Zongchao ^a   Berendzen, Kristen ^a   Zhong, Li ^a   Surolia, Ira ^a   Chouthai, Nitin ^a   Zhao, Weihong ^a,b   Maina, Njeri ^a,c   Srivastava, Arun ^a   Stacpoole, Peter W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AAV vector; Dichloroacetate; Gene therapy; Pyruvate dehydrogenase deficiency

Indexed keywords

COMPLEMENTARY DNA; DICHLOROACETIC ACID; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE E1 ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CELL LINE; COMPARATIVE STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY; SEROTYPE; SKIN FIBROBLAST; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

CELLS, CULTURED; DEPENDOVIRUS; DICHLOROACETATE; FIBROBLASTS; GENE THERAPY; GENETIC VECTORS; HUMANS; PYRUVATE DEHYDROGENASE (LIPOAMIDE); PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY DISEASE; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; CYTOMEGALOVIRUS;

EID: 40849119725     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2007.10.131     Document Type: Article

References (19)

1. Smolle M., Prior A.E., Brown A.E., Cooper A., Byron O., and Lindsay J.G. A new level of architectural complexity in the human pyruvate dehydrogenase complex. J. Biol. Chem. 281 (2006) 19772-19780
2. Robinson B.H. Lactic academia: disorders of pyruvate carboxylase and pyruvate dehydrogenase. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eighth ed. (2001), McGraw-Hill, New York 2275-2296
3. P.W. Stacpoole, L.R. Gilbert, Pyruvate dehydrogenase complex deficiency, in: R.H. Glew, M.D. Rosenthal (Eds.), Clinical Studies in Medical Biochemistry, third ed., Oxford University Press, Oxford, pp. 77-88.
4. Debray F.G., Lambert M., Chevalier I., Robitaille Y., Decarie J.C., Shoubridge E.A., Robinson B.H., and Mitchell G.A. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Pediatrics 119 (2007) 722-733 G.A
5. Lissens W., De Meirleir L., Seneca S., Liebaers I., Brown G.K., Brown R.M., Ito M., Naito E., Kuroda Y., Kerr D.S., Wexler I.D., Patel M.S., Robinson B.H., and Seyda A. Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum. Mutat. 15 (2000) 209-219
6. Cameron J.M., Levandovskiy V., Mackay N., Tein I., and Robinson B.H. Deficiency of pyruvate dehydrogenase caused by novel and known mutations in the E1alpha subunit. Am. J. Med. Genet. A 131 (2004) 59-66
7. Wexler I.D., Hemalatha S.G., McConnell J., Buist N.R., Dahl H.H., Berry S.A., Cederbaum S.D., Patel M.S., and Kerr D.S. Outcome of pyruvate dehydrogenase deficiency treatment with ketogenic diets: studies in patients with identical mutations. Neurology 49 (1997) 1655-1661
8. Berendzen K., Theriaque D.W., Shuster J., and Stacpoole P.W. Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrian 6 (2006) 126-135
9. Stacpoole P.W., Kerr D.S., Barnes C., Bunch S.T., Carney P.R., Fennell E.M., Felitsyn N.M., Gilmore R.L., Greer M., Henderson G.N., Hutson A.D., Neiberger R.E., O'Brien R.G., Perkins L.A., Quisling R.G., Shroads A.L., Shuster J.J., Silverstein J.H., Theriaque D.W., and Valenstein E. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 115 (2006) 1519-1531
10. Stacpoole P.W., Owen R., and Flotte T.R. The pyruvate dehydrogenase complex as a target for gene therapy. Curr. Gene Ther. 3 (2003) 239-245
11. Owen IV R., Lewin A.P., Peel A., Wang J., Guy J., Hauswirth W.W., Stacpoole P.W., and Flotte T.R. Recombinant adeno-associated virus vector-based gene transfer for defects in oxidative metabolism. Hum. Gene Ther. 11 (2000) 2067-2078
12. Owen IV R., Mandel R.J., Ammini C.V., Conlon T.J., Kerr D.S., Stacpoole P.W., and Flotte T.R. Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectors. Mol. Ther. 6 (2002) 394-399
13. Han Z., Gorbatyuk M., Thomas Jr. J., Lewin A.S., Srivastava A., and Stacpoole P.W. Down-regulation of expression of rat pyruvate dehydrogenase E1alpha gene by self-complementary adeno-associated virus-mediated small interfering RNA delivery. Mitochondrion 7 (2007) 253-259
14. Evans O.B., and Stacpoole P.W. Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate. Biochem. Pharmacol. 31 (1982) 1295-1300
15. Morten K.J., Caky M., and Matthews P.M. Stabilization of the pyruvate dehydrogenase E1α subunit by dichloroacetate. Neurology 51 (1998) 1331-1335
16. Curry S.H., Chu P.I., Baumgartner T.G., and Stacpoole P.W. Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin. Pharmacol. Ther. 37 (1985) 89-93
17. Stacpoole P.W., Moore G.W., and Kornhauser D.M. Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N. Engl. J. Med. 298 (1978) 526-530
18. Thai S.F., Allen J.W., DeAngelo A.B., George M.H., and Fuscoe J.C. Detection of early gene expression changes by differential display in the livers of mice exposed to dichloroacetic acid. Carcinogenesis 22 (2001) 1317-1322
19. C.V. Ammini, P.W. Stacpoole, Biotransformation, toxicology and pharmacogenomics of dichloroacetate, in: Natural Production of Organohalogen Compounds, G.W. Gribble, (Ed.), vol. 3/P in the series The Handbook of Environmental Chemistry, Springer-Verlag, Berlin, New York, 2003, pp. 215-234.